Towards optimal treatment for latent Mycobacterium tuberculosis infection

Lancet Respir Med. 2019 Mar;7(3):195-197. doi: 10.1016/S2213-2600(19)30036-0.

Authors

Ibrahim Abubakar¹, Jeremiah Chakaya², Markus Maeurer³, Alimuddin Zumla⁴

Affiliations

¹ University College London Institute for Global Health, University College London, London, UK.
² Union Headquarters, International Union Against Tuberculosis and Lung Disease, Paris, France; Department of Medicine, Kenyatta University, Nairobi, Kenya.
³ Champalimaud Foundation, Centre for the Unknown, Avenida Brasília, Lisbon, Portugal.
⁴ Division of Infection and Immunity, Center for Clinical Microbiology, University College London, London, UK; National Institute of Health Research Biomedical Research Centre, University College London Hospitals, London NW1 2PG, UK. Electronic address: a.zumla@ucl.ac.uk.

PMID: 30823969
DOI: 10.1016/S2213-2600(19)30036-0

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Antitubercular Agents* / administration & dosage
Antitubercular Agents* / adverse effects
Asymptomatic Diseases / epidemiology
Asymptomatic Diseases / therapy
Disease Progression
Endemic Diseases
Humans
Latent Tuberculosis* / diagnosis
Latent Tuberculosis* / epidemiology
Latent Tuberculosis* / immunology
Latent Tuberculosis* / therapy
Mycobacterium tuberculosis* / drug effects
Mycobacterium tuberculosis* / isolation & purification
Patient Care Management* / methods
Patient Care Management* / organization & administration
Patient Care Management* / standards
Practice Guidelines as Topic / standards*
Risk Assessment
Risk Factors
Secondary Prevention* / methods
Secondary Prevention* / standards
World Health Organization

Substances

Antitubercular Agents

Grants and funding